Murat Yildiz
Cohort Study comparing Corpus Callosum Atrophy as a marker of later development of cognitive impairment in patients with early and remitting relapsing multiple sclerosis
Mar 14, 2011Even in early stages of multiple sclerosis (MS), cognitive dysfunction is a leading cause of disability. It can have profound social and economic consequences for patients and their families. Cognitive impairment is affecting up to 65% of MS patients...
Clinical Studies - Mar 14, 2011 - May 31, 2011
Completed
Project leader: Yildiz Murat
Members: Vehoff Jochen, Müller Stefanie
Neurocognitive changes in patients with remitting relapsing multiple sclerosis treated with Natalizumab
Jan 1, 2011Neurocognitive changes in patients with remitting relapsing multiple sclerosis treated with Natalizumab
Clinical Studies - Jan 1, 2011 - Dec 31, 2012
Completed
Project leader: Yildiz Murat, Müller Stefanie
Tenere: A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis
May 3, 2010Primary: To assess the effectiveness of 2 doses of teriflunomide in comparison to interferon-beta 1a, evaluated by the time to failure, with failure being defined as either relapse or permanent study treatment discontinuation for any cause whichever...
Clinical Studies - May 3, 2010 - Jun 30, 2011
Completed
Project leader: Putzki Norman
Members: Yildiz Murat, Siebel Philip, Vehoff Jochen, Coco Orazio, Müller Anna, Müller Stefanie
Fatigue in Multiple Sclerosis now and then: a cross-sectional study
Nov 30, 2009Fatigue is one of the major concerns of MS patients. Disease modifying drugs (DMD) may have an impact on fatigue prevalence and severity. The current study aims to analyze fatigue severity with new disease modifying agents compared to previous invest...
Clinical Studies - Nov 30, 2009 - Apr 30, 2009
Completed
Project leader: Putzki Norman
Members: Yildiz Murat
Selective S1P1 receptor agonist in Patients with Relapsing-Remitting Multiple Sclerosis
Nov 1, 2009Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding phase IIb study to evaluate the efficacy, safety, and tolerability of three doses of an oral S1P1 receptor agonist, administered for twenty-four weks in patients...
Clinical Studies - Nov 1, 2009 - Nov 1, 2010
Completed
Project leader: Putzki Norman
Members: Yildiz Murat, Müller Anna, Siebel Philip, Müller Stefanie
Subkutane Mehrfachdosierungen von LY2127399, einem menschlichen Anti-BAFF-Antikörper, bei Patienten mit schubförmig remittierender multipler Sklerose
Nov 1, 2009Diese Phase II Studie soll Daten zur Dosisfindung zu LY2127399 bei subkutaner (s.c.) Injektion bei Patienten mit schubförmig remittierender multipler Sklerose (relapsing-remitting multiple sclerosis, RRMS) liefern. LY2127399 ist ein auf den Botenstof...
Clinical Studies - Nov 1, 2009 - May 1, 2011
Aborted
Project leader: Putzki Norman
Members: Yildiz Murat, Müller Anna
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Sep 24, 2009Randomized, Placebo-Controlled Phase II Monocentric Trial for the Neuroprotective Effect of Lamotrigine Plus Interferon Beta 1a 30mcg Once Weekly Intramuscular in Patients With Relapsing-Remitting Multiple Sclerosis. Primary Outcome Measures: N-Ace...
Clinical Studies - Sep 24, 2009 - Sep 24, 2011
Automatically Closed
Project leader: Putzki Norman
Members: Yildiz Murat, Müller Anna, Siebel Philip
A prospective MR spectroscopy study to investigate axonal loss in different stages of multiple sclerosis
Jul 24, 2009Die Multiple Sklerose (MS) ist die häufigste chronisch-entzündliche Erkrankung von Gehirn und Rückenmark. Sie betrifft vor allem Menschen im frühen und mittleren Erwachsenenalter. In der Schweiz leben rund 10.000 Menschen mit MS. Während man früher d...
Clinical Studies - Jul 24, 2009 - Sep 24, 2011
Completed
Project leader: Putzki Norman
Members: Müller Anna, Yildiz Murat, Siebel Philip
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of dimethyl fumarate (BG00012) in Subjects with Relapsing-Remitting Multiple Sclerosis
Oct 1, 2008Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of dimethyl fumarate in Subjects with Relapsing-Remitting Multiple Sclerosis primary objective: determine wether dimethyl fumarat...
Clinical Studies - Oct 1, 2008 - Dec 1, 2010
Completed
Project leader: Putzki Norman, Müller Stefanie
Members: Müller Anna, Yildiz Murat, Siebel Philip